Alterity Therapeutics ATHE shares moved upwards by 95.9% to $5.7 during Thursday's pre-market session. The market value of their outstanding shares is at $49.8 million. T ...

The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green Tectonic Therapeutic, Inc. (TECX) is up over ...

Inhibikase Therapeutics announced disappointing results from a Phase 2 trial for its Parkinson’s disease drug, risvodetinib, ...

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

Inhibikase Therapeutics is slamming the brakes on its Parkinson’s disease program after the candidate failed to improve ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ...

Inhibikase Therapeutics, Inc. (IKT), a biopharmaceutical company with a market capitalization of $189.48 million, has announced the halting of further development of its Parkinson's disease drug, ...

Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as eating ...

Quite a few insiders have dramatically grown their holdings in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) over the past 12 months. An insider's optimism about the company's prospects is a positive ...

Shares of the company hit their highest yearly value of US$3.98 on January 3. Inhibikase Therapeutics is developing protein kinase inhibitor therapeutics for modifying the course of ...